156 related articles for article (PubMed ID: 12225332)
1. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
Hino K; Kitase A; Satoh Y; Fujiwara D; Yamaguchi Y; Korenaga M; Shingai Y; Konishi T; Yamashita S; Uchida K; Mori K; Hanada H; Kodama T; Nukui K; Okita K
J Viral Hepat; 2002 Sep; 9(5):370-6. PubMed ID: 12225332
[TBL] [Abstract][Full Text] [Related]
2. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
Lok AS; Everhart JE; Wright EC; Di Bisceglie AM; Kim HY; Sterling RK; Everson GT; Lindsay KL; Lee WM; Bonkovsky HL; Dienstag JL; Ghany MG; Morishima C; Morgan TR;
Gastroenterology; 2011 Mar; 140(3):840-9; quiz e12. PubMed ID: 21129375
[TBL] [Abstract][Full Text] [Related]
3. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
[TBL] [Abstract][Full Text] [Related]
4. The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Sone Y; Hisanaga Y
Cancer; 2000 Jan; 88(1):58-65. PubMed ID: 10618606
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
6. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
[TBL] [Abstract][Full Text] [Related]
7. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis.
Cheinquer N; Cheinquer H; Wolff FH; Coelho-Borges S
Braz J Infect Dis; 2010; 14(5):457-61. PubMed ID: 21221473
[TBL] [Abstract][Full Text] [Related]
8. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.
Yoshida H; Tateishi R; Arakawa Y; Sata M; Fujiyama S; Nishiguchi S; Ishibashi H; Yamada G; Yokosuka O; Shiratori Y; Omata M
Gut; 2004 Mar; 53(3):425-30. PubMed ID: 14960528
[TBL] [Abstract][Full Text] [Related]
9. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Oct; 79(10):1485-90. PubMed ID: 17705189
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.
Kasahara A; Hayashi N; Mochizuki K; Takayanagi M; Yoshioka K; Kakumu S; Iijima A; Urushihara A; Kiyosawa K; Okuda M; Hino K; Okita K
Hepatology; 1998 May; 27(5):1394-402. PubMed ID: 9581697
[TBL] [Abstract][Full Text] [Related]
11. Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.
Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Hayashi K; Honda T
Oncology; 2001; 61(2):134-42. PubMed ID: 11528252
[TBL] [Abstract][Full Text] [Related]
12. Interferon for decreasing the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
Hayashi N; Kasahara A
Oncology; 2002; 62 Suppl 1():87-93. PubMed ID: 11868793
[TBL] [Abstract][Full Text] [Related]
13. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study.
Ikeda K; Saitoh S; Kobayashi M; Suzuki Y; Suzuki F; Tsubota A; Arase Y; Murashima N; Chayama K; Kumada H
J Gastroenterol Hepatol; 2001 Apr; 16(4):406-15. PubMed ID: 11354279
[TBL] [Abstract][Full Text] [Related]
14. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
Imai Y; Tamura S; Tanaka H; Hiramatsu N; Kiso S; Doi Y; Inada M; Nagase T; Kitada T; Imanaka K; Fukuda K; Takehara T; Kasahara A; Hayashi N
J Viral Hepat; 2010 Mar; 17(3):185-91. PubMed ID: 19709362
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
[TBL] [Abstract][Full Text] [Related]
16. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C.
Miyake Y; Iwasaki Y; Yamamoto K
Int J Cancer; 2010 Aug; 127(4):989-96. PubMed ID: 19957327
[TBL] [Abstract][Full Text] [Related]
18. Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C.
Hino K; Okita K
J Antimicrob Chemother; 2004 Jan; 53(1):19-22. PubMed ID: 14657083
[TBL] [Abstract][Full Text] [Related]
19. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.
Okanoue T; Minami M; Makiyama A; Sumida Y; Yasui K; Itoh Y
Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S89-91. PubMed ID: 16234069
[TBL] [Abstract][Full Text] [Related]
20. Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
Arase Y; Ikeda K; Tsubota A; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2004; 47(6):355-61. PubMed ID: 15564748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]